Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Decreases By 98.1%

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 341,500 shares, a decline of 98.1% from the December 31st total of 17,650,000 shares. Currently, 14.7% of the company’s stock are sold short. Based on an average daily trading volume, of 143,900 shares, the short-interest ratio is currently 2.4 days.

Institutional Trading of Bionano Genomics

A number of hedge funds have recently bought and sold shares of the business. Carret Asset Management LLC increased its position in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after purchasing an additional 40,055 shares during the last quarter. GSA Capital Partners LLP bought a new position in Bionano Genomics during the third quarter valued at about $46,000. Finally, Geode Capital Management LLC increased its holdings in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares during the last quarter. 11.35% of the stock is currently owned by institutional investors.

Bionano Genomics Stock Up 11.9 %

BNGO stock traded up $0.61 during trading on Thursday, reaching $5.75. The stock had a trading volume of 386,173 shares, compared to its average volume of 365,262. Bionano Genomics has a one year low of $4.95 and a one year high of $81.00. The company’s 50 day moving average is $12.97 and its two-hundred day moving average is $21.32. The company has a quick ratio of 0.99, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $672.29 million, a price-to-earnings ratio of -2.48 and a beta of 2.22.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.